About Inhalon 

Inhalon Biopharma is a startup immunotherapy company developing an inhaled antibody platform for treating a variety of acute respiratory infections. Our intellectual property includes multiple approved U.S. and EU patents broadly covering the composition and use of aerosolized antibodies, licensed from The University of North Carolina at Chapel Hill and Johns Hopkins University.

We are backed by leading life science angel investors, Life Science Angels, Band of Angels, Sand Hill Angels, Breakout Labs and individual investors. The U.S. Army Medical Research and Development Command has awarded Inhalon a contract to conduct a Phase 1/2a clinical study for the treatment of COVID-19 in outpatients. The muco-trapping technology is funded by more than $18 million in grants from the National Institutes of Health.

 

Leadership

John Whelan

  • Grey LinkedIn Icon

President, Chief Executive Officer and Director

John has over 20 years of experience leading venture-backed and public biotech companies. He has worked in early and late-stage companies taking products from discovery through NDA submission. He has contributed to the growth of these companies by building skilled, effective management teams and raising over $240M in funding through financings and collaborations.

 

Most recently John held the role of President and COO at Neuraltus Pharmaceuticals, a private company developing a treatment for amyotrophic lateral sclerosis (ALS). Prior to Neuraltus, Mr. Whelan held executive leadership positions with several life science companies, including President, CEO and Board Director at Heron Therapeutics where he led the company’s turnaround. Earlier, he was COO and CFO at Raven biotechnologies, where he led the sale of the company to MacroGenics.

Sam Lai, PhD

  • Grey LinkedIn Icon

Founder, Chief Scientific Officer and Director

Sam is the founder, chief scientific officer and director of Inhalon Biopharma, with a research background in pioneering the nanoparticle-based delivery of bioactive molecules to mucosal tissues. His prior inventions formed the basis of multiple startup companies, and multiple FDA-approved drugs.

 

As professor at the University of North Carolina at Chapel Hill, Sam has established a rigorous research program at the interface of engineering, immunology, biophysics and biomaterials. His lab pioneered Inhalon’s platform technology and has also spun off other companies.

 

He graduated with a B.S. and Ph.D. in chemical and biomolecular engineering from Cornell and Johns Hopkins University. He is the recipient of a Packard Fellowship in Science and Engineering, and an NSF CAREER Award for his pioneering work on muco-trapping antibodies.

Thomas Moench, MD

Vice President, Clinical

Thomas is an infectious disease physician/scientist and served on the faculty of JHU School of Medicine for over 10 years. As Chief Medical Officer at Mapp, he oversaw the clinical development of ZMapp, a cocktail of 3 mAbs for treatment of Ebola, as well as the preclinical development and clinical study of MB66, a vaginal film loaded with two anti-viral mAbs.  He was the Principle Investigator (PI) of over $144M in BARDA funding for development of ZMapp and co-PI of a $13.3M NIAID-sponsored multicenter microbicide program that funded the MB66 work.  As such, he has experience in both clinical development and the industrialization of biologics as well as drug-device combinations for infectious disease.

 
 

Board of Directors

John Whelan

  • Grey LinkedIn Icon

President, Chief Executive Officer and Director

John has over 20 years of experience leading venture-backed and public biotech companies. He has worked in early and late-stage companies taking products from discovery through NDA submission. He has contributed to the growth of these companies by building skilled, effective management teams and raising over $240M in funding through financings and collaborations.

 

Most recently John held the role of President and COO at Neuraltus Pharmaceuticals, a private company developing a treatment for amyotrophic lateral sclerosis (ALS). Prior to Neuraltus, Mr. Whelan held executive leadership positions with several life science companies, including President, CEO and Board Director at Heron Therapeutics where he led the company’s turnaround. Earlier, he was COO and CFO at Raven biotechnologies, where he led the sale of the company to MacroGenics.

Sam Lai, PhD

  • Grey LinkedIn Icon

Founder, Chief Scientific Officer and Director

Sam is the founder, chief scientific officer and director of Inhalon Biopharma, with a research background in pioneering the nanoparticle-based delivery of bioactive molecules to mucosal tissues. His prior inventions formed the basis of multiple startup companies, and multiple FDA-approved drugs.

 

As professor at the University of North Carolina at Chapel Hill, Sam has established a rigorous research program at the interface of engineering, immunology, biophysics and biomaterials. His lab pioneered Inhalon’s platform technology and has also spun off other companies.

 

He graduated with a B.S. and Ph.D. in chemical and biomolecular engineering from Cornell and Johns Hopkins University. He is the recipient of a Packard Fellowship in Science and Engineering, and an NSF CAREER Award for his pioneering work on muco-trapping antibodies.

Winnie H Wan, PhD

  • Grey LinkedIn Icon

Serial Entrepreneur

Winnie has extensive experience launching and building life science companies and has successfully commercialized disruptive technologies that resulted in successful exits. These technologies include the analytical systems for drug development at ForteBio, Inc. (acquired by Pall Corp.); the anatomical pathology systems for cancer diagnosis at Becton Dickinson, the cell analysis systems at Guava Technologies, Inc. (acquired by Millipore); and the HIV drug testing model at SyStemix, Inc. (acquired by Novartis).

 

Investors

cvfbuvztoyejmo6q0wff.png
BreakoutLabs_logo.png
Band_of_Angels_(investors)_logo.png
static1_edited.png

Partners

 
logo-MTEC.png